Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine
Executive Summary
Novartis is trying to convince FDA that its squalene vaccine adjuvant MF59 is a non-threatening vaccine component that does not deserve to get caught in a long regulatory review of new vaccine technologies
You may also be interested in...
Fluad Adjuvant Could Come Under Fire At Advisory Committee
CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.
Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.
If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts
Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.
If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts